a r t i c l e s JAK2, a member of the Janus family of protein tyrosine kinases (JAK1-JAK3, Tyk2), associates with the cytoplasmic regions of various cytokine receptors, including those for growth hormone, erythropoietin, leptin, interferon-γ, and interleukin 3 (IL-3) and . JAK2 is activated through cytokine-mediated receptor dimerization or rearrangement, and it signals through the JAK-STAT (signal transducer and activator of transcription) pathway 2 , which is essential for myeloid cell development, proliferation and survival, as well as for the initial stages of the immune response.
a r t i c l e s JAK2, a member of the Janus family of protein tyrosine kinases (JAK1-JAK3, Tyk2), associates with the cytoplasmic regions of various cytokine receptors, including those for growth hormone, erythropoietin, leptin, interferon-γ, and interleukin 3 (IL-3) and IL-5 (ref. 1) . JAK2 is activated through cytokine-mediated receptor dimerization or rearrangement, and it signals through the JAK-STAT (signal transducer and activator of transcription) pathway 2 , which is essential for myeloid cell development, proliferation and survival, as well as for the initial stages of the immune response.
JAKs possess an N-terminal FERM (band 4.1, ezrin, radixin, moesin) domain, a Src homology-2 (SH2)-like domain, a pseudokinase domain (JAK homology-2, JH2) and a C-terminal tyrosine kinase domain (JH1). Extensive biochemical studies on JAKs 1 have established that (i) the FERM domain is primarily responsible for the association of JAKs with cytokine receptors; (ii) the SH2-like domain does not function as a conventional phosphotyrosine-binding domain, and its precise role is unclear; (iii) JH1 is activated via transphosphorylation of tandem tyrosines in the activation loop (Tyr1007 and Tyr1008 in JAK2); and (iv) JH2 regulates the activity of JH1. At present, structural information for JAKs is limited to JH1 (refs. 3-6) .
Mutations in human JAK genes cause MPNs, which are clonal proliferative disorders affecting different myeloid lineages 7 . The molecular etiologies for the more common MPNs, namely polycythemia vera, essential thrombocythemia and primary myelofibrosis, have been identified and shown to be caused in most cases by mutations in the JH2 region of JAK2 (refs. 7,8) . Mutations in JH2 of JAK1-JAK3 have also been linked to leukemias, such as acute lymphoblastic leukemia and acute myeloid leukemia 8 . All of these mutations result in constitutive tyrosine kinase activity of JAK2. V617F in JH2 of JAK2 is the most commonly identified mutation in MPNs and is responsible for >95% of cases of polycythemia vera and ~50% of cases of essential thrombocythemia and primary myelofibrosis [9] [10] [11] [12] . This mutation has also recently been implicated in non-small cell lung cancer 13 .
The molecular mechanisms underlying JH2 regulation of JH1 in JAKs are poorly understood. The MPN pathogenic data imply an inhibitory function for JH2, but some mutations in JH2 of JAK3 lead to loss of function, causing severe combined immunodeficiency (SCID) 14 , suggesting that JH2 may have a positive regulatory function. The dual regulatory nature of JH2 is supported by biochemical studies of JH2 deletion mutants, which showed that basal activity is elevated but cannot be further stimulated by cytokine, and that the activity is well below that of cytokine-stimulated full-length JAK2 (refs. 15-17) . A molecular model for an autoinhibitory interaction between JH2 and JH1, which would hinder trans-phosphorylation of the JH1 activation loop, has been proposed 18 but never verified experimentally. The molecular nature of the positive (stimulatory) interaction mediated by JH2, which would facilitate trans-phosphorylation of JH1, has received far less attention.
We recently showed that, despite containing several amino acid substitutions thought to render it inactive, JAK2 JH2 is catalytically active, and it phosphorylates two negative regulatory sites in JAK2, Ser523 and Tyr570 (ref. 19) . To gain insights into the molecular basis for this catalytic activity and for the constitutive activity of the pathogenic mutant V617F, we undertook crystallographic and biochemical studies of JAK2 a r t i c l e s JH2. The results show that JAK2 JH2 adopts the fold of a eukaryotic protein kinase but binds Mg-ATP via a noncanonical mode. Moleculardynamics simulations in conjunction with the crystallographic studies indicate that the mutation V617F rigidifies an α-helix (αC) in the N lobe of JH2, stabilizing the JH2 stimulatory interaction necessary for JAK2 activation.
RESULTS

Crystal structure of JAK2 JH2
We initially engineered two baculoviruses to encode human JAK2 JH2, residues 536-827, for both wild type and V617F. We expressed these two proteins in soluble form in insect cells, but the proteins showed signs of aggregation during purification and did not yield crystals. On the basis of our homology model of JAK2 JH2, we identified three putative solvent-exposed hydrophobic residues (all in the C lobe) for possible substitution: Trp659, Trp777 and Phe794 (each of which is not conserved in JAKs). Full-length JAK2 bearing the mutations W659A, W777A and F794H was phosphorylated in cells to the same extent as for wild type (data not shown). The mutated versions of wild-type (JH2-WT) and V617F JH2 (JH2-VF), also with a new C terminus at residue 812 (see Online Methods for details), expressed at higher levels, were better behaved during purification and readily yielded crystals.
We obtained crystal structures of JH2-WT without nucleotide (apo; 2.0-Å resolution) and with Mg-ATP bound (cocrystallization; 1.75-Å resolution), each with one JH2 molecule per asymmetric unit.
Data collection and refinement statistics appear in Table 1 . JAK2 JH2 adopts the prototypical serine-threonine-and tyrosine-kinase fold, with an N lobe comprising a five-stranded β-sheet and one α-helix (αC), and a C lobe that is mainly α-helical (Fig. 1a) . The domain structure of JH2 begins at Phe537 and ends at Leu808, residues that are conserved in JH2 of JAKs. Notable overall features of the JH2 structure include a relatively short (nonphosphorylatable) activation loop (seven residues shorter than in JAK2 JH1), which terminates in an α-helix, and an extended loop between β-strand 7 (β7) and β8 (eight residues longer than the corresponding loop in JH1).
JH2s of JAKs lacks several residues that, in canonical protein kinases, are important for catalysis (Supplementary Fig. 1 ). The catalytic loop in canonical protein kinases contains a conserved aspartate that plays a key role in the phosphoryl transfer reaction. In JAK JH2s, an asparagine (Asn673 in JAK2) replaces the aspartate. The activation loop of canonical protein kinases begins with an Asp-Phe-Gly (DFG) sequence motif, whereas JAK JH2s contain Asp-Pro-Gly (DPG). Finally, in canonical protein kinases, a conserved lysine in β3 (Lys581 in JAK2) interacts by salt bridge with a conserved glutamate in αC, which is replaced by alanine or threonine in JAK JH2s (Ala597 in JAK2).
ATP binding mode and comparison with other protein kinases
As with canonical protein kinases, Mg-ATP binds in the cleft between the N and C lobes of JAK2 JH2 (Fig. 1a,b) . The structures of JH2-WT with and without bound Mg-ATP are very similar, with an r.m.s. deviation in Cα positions (residues 537-808) of only 0.44 Å. The apo structure exhibits a closed lobe configuration, which is not appreciably altered upon Mg-ATP binding. This trait is probably due in part to a Arg715 at the end of the activation loop, which in both the apo and ATP-bound forms of JH2 makes a hydrogen bond with Thr555 in the nucleotide-binding loop (Fig. 1b) . One salient difference between the apo and Mg-ATP-bound structures is found in αC. In the apo structure, αC is disrupted midway by an intercalating water molecule that bridges backbone atoms Phe594 (oxygen) and Ala598 (nitrogen) in the helix. Binding of Mg-ATP displaces this water molecule, but the backbone hydrogen-bonding in αC remains irregular (Supplementary Fig. 2 ).
There are several features that distinguish the ATP-binding mode in JH2 from that in canonical protein kinases (Fig. 1b) . In JH2, Leu579 (β3) from the N lobe flanks the adenine base, whereas alanine is highly conserved at this position (VA(V/I)K motif) in canonical protein kinases. Two threonine residues in the nucleotide-binding loop of JH2 are hydrogenbonded to ATP phosphate groups: Thr555 with the γ-phosphate and Thr557 with the β-phosphate. Thr557 is typically a glycine in canonical protein kinases (GXGXXG motif, where X is any amino acid). The 'gatekeeper' residue in the back of the ATP-binding cleft is typically hydrophobic, but in JH2 it is a glutamine (Gln626), which is hydrogenbonded to the adenine base and to Asp699 (DPG) in the activation loop.
The structure contains a single Mg 2+ ion, which is coordinated by Asn678 (catalytic loop), an oxygen atom from each of the three ATP phosphate groups and one water molecule (Fig. 1b) . In canonical protein kinases, such as (serine-threonine) protein kinase A (PKA) 20 or the insulin receptor tyrosine kinase 21 , two Mg 2+ ions are present, and the aspartate of the DFG motif coordinates both ions (Supplementary Fig. 3a) . Rather than coordinating a Mg 2+ ion, Asp699 in JH2 (DPG) interacts through a salt bridge with Lys581, the conserved β3 lysine. This interaction evidently substitutes for the canonical β3 lysine-αC glutamate salt bridge. A superposition of the active sites of JH2 and PKA reveals that the γ-phosphate of ATP in the JH2 structure is positioned for phosphoryl transfer (Supplementary Fig. 3a) .
JH2s of JAKs share several sequence characteristics with Her3 (ErbB3), a member of the epidermal growth factor receptor family.
Her3 was also characterized as a pseudokinase but was recently shown to possess weak catalytic activity 22 . In both kinases, the conserved glutamate in αC is absent, and asparagine replaces aspartate in the catalytic loop. In the Her3 structure 22, 23 , Asp833 from the DFG motif is connected by salt bridge to the β3 lysine (Lys723), similar to Asp699 in JAK2 JH2, but it also coordinates the lone Mg 2+ ion (Supplementary Fig. 3b) . The γ-phosphate of the nucleotide is in a different position in the two structures, possibly as a result of the utilization of the nonhydrolyzable analog AMP-PNP for Her3 versus ATP for JAK2.
Cis-versus trans-autophosphorylation of Ser523 and Tyr570
We determined whether the two sites we had identified previously 19 , Ser523 and Tyr570, are autophosphorylated via a cis or trans mechanism. Simple modeling based on the JH2 crystal structure suggests that Ser523, in the SH2-JH2 linker, could possibly reach the JH2 active site to be autophosphorylated in cis, whereas Tyr570 in the β2-β3 loop of JH2, far removed from the active site ( Supplementary Fig. 4) , would necessarily be autophosphorylated in trans. As described previously 19 , we purified a longer form of JH2 (residues 513-827, which include Ser523) by anion-exchange chromatography, which yielded two JH2 peaks representing unphosphorylated and Ser523-phosphorylated JH2. We incubated unphosphorylated JH2 with Mn-[γ-32 P]ATP at several different protein concentrations and for several time points. 
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The data show that the phosphorylation level of Ser523 is independent of JH2 concentration, consistent with autophosphorylation in cis (Fig. 2,  top) . Moreover, these data provide further proof, beyond expression of a catalytically inactive JH2 mutant (K581A) 19 , that Ser523 is phosphorylated by JH2 and not by a contaminating protein kinase, which would necessarily be concentration dependent. Similarly, we performed an autophosphorylation reaction with Ser523-phosphorylated JH2 (from the second ion-exchange peak). In this case, the phosphorylation level of Tyr570 was concentration dependent, consistent with autophosphorylation in trans (Fig. 2, bottom) .
Crystal structure of JAK2 JH2 V617F
We obtained a crystal structure at 2.0-Å resolution of JH2-VF, with Mg-ATP bound, in the same monoclinic lattice as JH2-WT ( Table 1) . Val617 is situated in the β4-β5 loop in the N lobe of JH2 (Fig. 1a) . Overall, the structures of JH2-VF and JH2-WT are highly similar, with an r.m.s. deviation in Cα positions (residues 537-808) of 0.76 Å (Fig. 3a) . The mode of nucleotide binding to JH2-VF is indistinguishable from that of JH2-WT. Substantive structural deviations between JH2-VF and JH2-WT occur in αC and in the β3-αC and β4-β5 loops. Most notably, in contrast to its distorted structure in JH2-WT, αC in JH2-VF exhibits continuous backbone hydrogenbonding and is extended by an additional turn on the N-terminal end (Supplementary Fig. 2 ). Phe617 (replacing valine) causes a rotation in the phenyl ring of Phe595 (αC) and induces a major shift in the side chain position of neighboring Phe594 (Fig. 3a) . Phe617, Phe595 and Phe594 form π-stacking interactions (T-shaped) (Fig. 3b) , with a closest inter-ring carbon-carbon distance of 3.8 Å for both Phe617-Phe595 and Phe595-Phe594. The Phe594 perturbation slightly alters the side chain position of Lys581 (Fig. 3b) , which might explain why the catalytic activity of JH2 is impaired in V617F 19 .
Molecular dynamics simulations
To explore further the structural differences between JH2-WT and JH2-VF and the relative stability of αC, we performed long-scale (~20 µs) molecular-dynamics simulations of the two proteins in their apo forms. The simulations show that αC in wild-type JH2 is prone to melting and that Phe617 stabilizes the helix (Fig. 3c) , corroborating the crystallographic data. Stabilization of αC is likely due in part to the π-stacking interactions between Phe617, Phe595 and Phe594. However, during the 20-µs simulation, these three residues are in contact only transiently, suggesting that Phe617 stabilizes αC through indirect mechanisms as well. The simulations also indicate that, overall, JH2 is intrinsically flexible in comparison with other protein kinases. The catalytic loop is one of the more stable polypeptide segments in protein kinases, and, over the simulation, the r.m.s. deviation in Cα positions for the catalytic loop of JH2-WT (residues 671-678) was 1.99 Å versus 0.76 Å for the same eight residues in the catalytic loop of the Src tyrosine kinase (residues 384-391). This is probably due, at least in part, to the presence of a glycine in the JH2 catalytic loop (Gly672 in JAK2) in place of the canonical arginine (His-Arg-Asp (HRD) motif; Supplementary Fig. 1) . A small amino acid is required at this position to accommodate the shorter activation loop of JH2 and its divergent conformation.
Effects of JH2 mutations in full-length JAK2
To probe the importance of Phe594 and Phe595 in αC for the constitutive activity of V617F, we introduced the point mutations F594A or F595A into either hemagglutinin (HA)-tagged wild-type JAK2 or V617F (double mutants) and expressed the proteins in γ2A mammalian cells that lack endogenous JAK2. As observed previously, the basal (non-cytokine stimulated) activation state of JAK2 V617F, as measured by JH1 activation-loop phosphorylation (pTyr1007, pTyr1008), is markedly enhanced compared to wild-type JAK2 (Fig. 4) . The single point mutations in αC (F594A or F595A) did not substantially change the basal activation state of JAK2, but they caused a dramatic loss of constitutive activity of V617F (Fig. 4 and refs. 24,25 ). To investigate whether destabilization of αC by F595A could account for the loss of V617F activity, we performed molecular-dynamics simulations on the double mutant, F595A V617F. Indeed, F595A caused a reversion of αC stability back to the wild-type level, if not below (Fig. 3c) . Because F595A suppresses not only the hyperactivity of (proximal) V617F but also of R683G (β7-β8 loop; Supplementary Fig. 4 ) and even of T875N in JH1 (ref. 24) , our results suggest that F595A intrinsically destabilizes αC and that the structural integrity of αC is critical for the stimulatory interaction mediated by JH2.
Because destabilization of αC in the N lobe was found to suppress the constitutive activity of V617F, we asked what effect destabilization of the C lobe would have on JAK2 activity. For this purpose, we introduced the mutation F739R. Phe739 in αF is buried in the hydrophobic core of the C lobe ( Supplementary Fig. 4) , and mutation to arginine should severely destabilize the C lobe. In contrast to F594A and F595A, F739R showed a marked increase in basal phosphorylation of JAK2 in γ2A cells (Fig. 4) . As with F594A and F595A but to a lesser extent, F739R suppressed the activity of V617F. The behavior of F739R largely mimics that of the JAK2 JH2 deletion mutant 15 (increased but submaximal JAK2 activity) and, from the comparison with F595A (no increase in basal activity, major suppression of V617F activity), suggests that the C lobe plays a more important role in the JH2-mediated inhibitory interaction than it does in the stimulatory interaction.
DISCUSSION
The crystal structure of JAK2 JH2, a domain that was originally characterized as a pseudokinase but shown by us to possess catalytic activity 19 , reveals that it adopts a prototypical eukaryotic protein-kinase fold. Previously, we measured a K d of 1 µM for binding of the fluorescent ATP analog mant-ATP 19 , which is substantially lower than for typical protein kinases (K d = 36 µM for PKA 26 ). The higher affinity is evidently due to the additional noncanonical interactions with Mg-ATP described above (Fig. 1b) . The functional role of the high-affinity binding is not known, but it may be important for the structural stability of JH2, which is required for the JH2-mediated stimulatory interaction.
Previously, we mapped Ser523 and Tyr570 as JH2 phosphorylation sites 19 , which had been shown earlier to be important for maintaining low basal activity of JAK2 (refs. 27-30) . Here, we show that JH2 phosphorylates Ser523 in cis and Tyr570 in trans. It is conceivable that phosphorylation of these sites fortifies the inhibitory interaction mediated by JH2 through electrostatic interactions between pSer523 and pTyr570 and basic residues in JAK2 (presumably in JH1 or JH2). These data are all from the same two blots.
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These phosphorylation sites are not conserved in the other JAKs, which suggests that JAK2 may be the only JAK to possess this additional negative regulatory mechanism. Of note, JAK2 is the only JAK that transactivates via homodimeric cytokine receptors (for example, erythropoietin receptor and growth hormone receptor), which juxtapose two JAK2 molecules. Other JAKs (JAK2 included) transactivate via heterodimeric receptors, which juxtapose, for example, JAK1 and JAK3. Her3, like JH2 of JAKs, contains an asparagine in the catalytic loop in place of the canonical aspartate (Asn815 in Her3, Asn673 in JAK2 JH2; Supplementary Fig. 3b) . Quantum mechanics-molecular mechanics (QM-MM) simulations on Her3 provided theoretical support for phosphoryl transfer (via an associative mechanism) with asparagine at this key position 22 . Interestingly, when introduced into full-length JAK2, the mutation N673D (restoring the canonical aspartate) resulted in suppression of V617F hyperactivity (data not shown), suggesting that the noncanonical asparagine plays a positive role in JAK2 activation. We speculate that, because of the noncanonical mode of Mg-ATP binding in JH2, aspartate at this position (proximal to the γ-phosphate) might destabilize ATP binding as a consequence of (negative) charge repulsion.
The exact nature of the JH2-mediated inhibitory and stimulatory interactions that regulate JH1 activity is not known. The majority of MPN-causative mutations in JAK2 map to either the N lobe of JH2 (in exons 12 or 14) or the β7-β8 region (in exon 16; Supplementary Fig. 4) , with relatively few mutations mapping to JH1 (ref. 8 ). In addition, in a random mutagenesis study of JAK2 (encompassing the entire molecule) 31 , gain-of-function mutations mapped either to JH2 (the same regions: N lobe, β7-β8) or to residues just N-terminal to JH2, with no mutations in JH1. These considerations suggest that, rather than there being an autoinhibitory interaction between JH2 and JH1 (ref. 18 )-the prevailing model in the field-the domain interactions may predominantly involve JH2 itself: that is, JH2 dimerization both in the basal state on predimerized cytokine receptors 32 (inhibitory dimer) and after cytokine binding and receptor rearrangement (stimulatory dimer). Further structural and biochemical studies will be required to characterize the requisite molecular interactions.
MPN mutations in JH2 evidently drive formation of the stimulatory interaction in the basal state, either by destabilizing the inhibitory interaction (without compromising the ability of JH2 to form the stimulatory interaction) or by hyperstabilizing the stimulatory interaction. Our structural and mutagenesis data indicate that V617F is in the latter category. In addition, V617F and other MPN mutations tested 19 impair JH2 catalytic activity, which further enhances JAK2 (JH1) activity due to loss of Ser523 and Tyr570 phosphorylation (negative regulatory). Therefore, MPN mutations in JAK2 JH2 appear to achieve hyperactivity through a gain-of-function steric mechanism (on JH1) and a loss-of-function catalytic mechanism (on JH2).
Elucidation of the central role of JAK2 in the pathogenesis of MPNs and other human diseases has spurred development of smallmolecule inhibitors of JAK2. Numerous clinical trials with these inhibitors are ongoing, and the first JAK2 inhibitor (ruxolitinib) was recently approved by the US Food and Drug Administration, for treatment of myelofibrosis. All JAK inhibitors in clinical trials target JH1, which is identical in wild-type JAK2 and in most (JH2-based) MPN mutants, and side effects such as anemia and thrombocytopenia inevitably arise 33 . Because JH2 is a key regulatory domain and a hot spot for disease mutations, this domain represents an alternative small-molecule target. Our high-resolution structures of JAK2 JH2 should enable the design of such compounds.
METHODS
Methods and any associated references are available in the online version of the paper. 
